晚期卵巢癌新辅助治疗的必要性

参考文献：

［1］Van Meurs HS,Tajik P,Hof MH,et al.Which patients benefit most from primary surgery or neo-adjuvant chemotherapy in stage ⅢC or Ⅳ ovarian cancer?An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial［J］.Eur J Cancer，2013，49(15):3191-3201

［2］Kehoe S,Hook J,Nankivell M,et al.Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS):an open-label,randomised,controlled,non-inferiority trial［J］.Lancet，2015，386(9990):249-257

［3］Onda T,Satoh T,Saito T,et al.Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage Ⅲ/Ⅳ ovarian,tubal,and peritoneal cancers in a phase Ⅲ randomised trial:Japan Clinical Oncology Group Study JCOG0602［J］.Eur J Cancer，2016，64(1):22-31

［4］Fagotti A,Ferrandina G,Vizzielli G,et al.Phase Ⅲ randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load （SCORPION trial):final analysis of peri-operative outcome［J］.Eur J Cancer,2016,59(1):22-33

［5］Coleridge SL,Bryant A,Kehoe S,et al.Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer［J］.Cochrane Database Syst Rev,2021,7(7):CD005343

［6］Lyons Y, et al. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy. Int J Gynecol Cancer. 2020 Jun;30(6):845-852.

[7]  Rauh-Hain J A, Nitschmann C C, Worley M J, Jr., et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma [J]. Gynecol Oncol, 2013, 129(1): 63-8.

[8] Gao Y， Li Y， Zhang C， et al. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer:a retrospective study[J].J Ovarian Res，2019，12(1):85.